Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years

摘要: On September 19, 2014, CDC published the Advisory Committee on Immunization Practices (ACIP) recommendation for routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years, to be used in series with 23-valent polysaccharide (PPSV23) (1). This replaced previous that years should vaccinated a single dose PPSV23. As proxy estimating PCV13 and PPSV23 vaccination coverage before after implementation these revised recommendations, analyzed claims submitted reimbursement Centers Medicare & Medicaid Services (CMS). Claims from any time during beneficiary's enrollment Parts A (hospital insurance) B (medical since reaching age 65 were assessed beneficiaries continuously enrolled annual periods 2009, through 18, 2016. By 2016, 43.2% had at least 1 (regardless status), 31.5% 18.3% each either type highest who older, white, or chronic immunocompromising medical conditions than healthy adults. Implementation National Vaccine Committee's standards adult immunization practice assess status every patient encounter, recommend needed vaccines, administer refer vaccinating provider might help increase reduce risk pneumonia invasive disease older (2).